1e82995c-f318-4225-96d4-f1e98bcbf60b
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 47
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.330
- APICAL_JUNCTION+0.310
- HEDGEHOG_SIGNALING+0.310
- WNT_BETA_CATENIN_SIGNALING+0.300
- NOTCH_SIGNALING+0.290
- CHOLESTEROL_HOMEOSTASIS+0.250
- P53_PATHWAY+0.250
- COAGULATION+0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
- HYPOXIA+0.200
Top 10 suppressed
- E2F_TARGETS-0.520
- G2M_CHECKPOINT-0.480
- ANDROGEN_RESPONSE-0.400
- PROTEIN_SECRETION-0.400
- SPERMATOGENESIS-0.290
- UV_RESPONSE_DN-0.250
- ALLOGRAFT_REJECTION-0.220
- INTERFERON_GAMMA_RESPONSE-0.220
- MITOTIC_SPINDLE-0.210
- MTORC1_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a4322796-9189-48c2-9e7c-7b1493b5799a | — | — | 0.872 |
| 2 | 290b89f5-2a44-424b-b77d-a190dcb93e07 | — | — | 0.869 |
| 3 | R168 | — | — | 0.867 |
| 4 | a8235ad1-0c5f-4a0b-b595-85ef3a1e49ff | — | — | 0.860 |
| 5 | MDT-AP-1336 | Med | Medulloblastoma | 0.860 |
| 6 | c0054cf0-8f4b-47b6-a8fc-63a1fd36bcc7 | — | — | 0.854 |
| 7 | 05167d53-0b47-4131-bfa4-450b236b9fd5 | — | — | 0.848 |
| 8 | 1c3d6580-0dc8-4346-a4f7-0bb404d4a245 | — | — | 0.824 |
| 9 | MNG545 | — | — | 0.821 |
| 10 | SAMN03290915 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |